Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK

Aims We investigated use and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in UK practice. Methods People starting a GLP-1 receptor agonist (exenatide, liraglutide) or insulin (glargine, detemir, NPH) after a regimen of two or three oral glucose-lowering agents were identified from The Health Information Network observational primary care database (20072011). Mean change in HbA1c and body weight were compared at 1year between cohorts, adjusting for baseline characteristics. Results Baseline characteristics of GLP-1 receptor agonist (n=1123) vs. insulin (n=1842) users were HbA1c 78 vs. 84mmol/mol (9.3 vs. 9.8%) and BMI 38.2 vs. 30.9kg/m2. The GLP-1 receptor agonist cohort was younger, had shorter diabetes duration and follow-up, less microvascular disease and heart failure, higher estimated glomerular filtration rate and more use of oral glucose-lowering agents. Lower HbA1c reduction on GLP-1 receptor agonist [7 vs. 13mmol/mol (0.6 vs. 1.2%) (n=366 vs. 892)] was not statistically significant [adjusted mean difference 1.4 (95% CI 4.1, 1.2) mmol/mol], except in the highest HbA1c quintile [>96mmol/mol (>10.9%); adjusted mean difference 17.8 (28.6, 7.0) mmol/mol]. GLP-1 receptor agonist users lost weight [4.5 vs. +1.5kg; adjusted mean difference 4.7 (3.7, 5.8) kg; n=335 vs. 634]. A UK 6-month target reduction for GLP-1 receptor agonists of 11mmol/mol (1.0%) HbA1c and 3% weight was reached by 24.9% of those continuing treatment. Conclusions Those starting GLP-1 receptor agonists are heavier with better glycaemic control than those starting basal insulin. Subsequently, they have improved weight change, with similar HbA1c reduction unless baseline HbA1c is very high. The UK 6-month GLP-1 receptor agonist target is usually not reached.